Chronic myelomonocytic leukaemia - Pipeline Insight, 2021
![](/report_cover/8047/chronic-myelocytic-leukemia-cml-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chronic myelomonocytic leukaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic myelomonocytic leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic myelomonocytic leukaemia: Overview
Chronic myelomonocytic leukaemia (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser extent, the production of normal blood cells in the bone marrow.
'Chronic myelomonocytic leukaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic myelomonocytic leukaemia pipeline landscape is provided which includes the disease overview and Chronic myelomonocytic leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic myelomonocytic leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic myelomonocytic leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic myelomonocytic leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic myelomonocytic leukaemia Emerging Drugs
Further product details are provided in the report……..
Chronic myelomonocytic leukaemia: Therapeutic Assessment
This segment of the report provides insights about the different Chronic myelomonocytic leukaemia drugs segregated based on following parameters that define the scope of the report, such as:
Chronic myelomonocytic leukaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic myelomonocytic leukaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic myelomonocytic leukaemia drugs.
Chronic myelomonocytic leukaemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic myelomonocytic leukaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic myelomonocytic leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic myelomonocytic leukaemia: Overview
Chronic myelomonocytic leukaemia (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser extent, the production of normal blood cells in the bone marrow.
'Chronic myelomonocytic leukaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic myelomonocytic leukaemia pipeline landscape is provided which includes the disease overview and Chronic myelomonocytic leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic myelomonocytic leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic myelomonocytic leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic myelomonocytic leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic myelomonocytic leukaemia.
This segment of the Chronic myelomonocytic leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic myelomonocytic leukaemia Emerging Drugs
- Sabatolimab: Novarits Oncology
- Enasidenib: Servier
Further product details are provided in the report……..
Chronic myelomonocytic leukaemia: Therapeutic Assessment
This segment of the report provides insights about the different Chronic myelomonocytic leukaemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic myelomonocytic leukaemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic myelomonocytic leukaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic myelomonocytic leukaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic myelomonocytic leukaemia drugs.
Chronic myelomonocytic leukaemia Report Insights
- Chronic myelomonocytic leukaemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic myelomonocytic leukaemia drugs?
- How many Chronic myelomonocytic leukaemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic myelomonocytic leukaemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic myelomonocytic leukaemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic myelomonocytic leukaemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novarits Oncology
- Servier
- Eltrombopag
- Immune-Onc Therapeutics
- H3 Biomedicine
- Chroma Therapeutics
- Nerviano Medical Sciences
- Astex Pharmaceuticals
- Takeda Oncology
- Argenx
- Kura Oncology
- Incyte Corporation
- Genentech, Inc.
- Sensei Biotherapeutics
- Pfizer
- BioLite, Inc.
- Newave Pharmaceutical Inc
- Ellipses Pharma
- Eli Lilly and Company
- Aprea Therapeutics
- Treadwell Therapeutics
- Prelude Therapeutics
- Onconova Therapeutics
- Immune Pharmaceuticals
- Teva Pharmaceutical Industries
- Sabatolimab
- Enasidenib
- IO 202
- H3B 8800
- Tefinostat
- NMS 03592088
- Guadecitabine
- Pevonedistat
- Cusatuzumab
- Tipifarnib
- Ruxolitinib
- Venetoclax
- SNS-301
- Cobimetinib
- Glasdegib
- BLEX 404
- LP-108
- Canakinumab
- EP0042
- LY3410738
- APR-246
- CFI-400945
- PRT543
- Rigosertib
- Histamine dihydrochloride injection
- Arsenic trioxide
Introduction
Executive Summary
Chronic myelomonocytic leukaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tefinostat: Chroma Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Enasidenib: Servier
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic myelomonocytic leukaemia Key Companies
Chronic myelomonocytic leukaemia Key Products
Chronic myelomonocytic leukaemia- Unmet Needs
Chronic myelomonocytic leukaemia- Market Drivers and Barriers
Chronic myelomonocytic leukaemia- Future Perspectives and Conclusion
Chronic myelomonocytic leukaemia Analyst Views
Chronic myelomonocytic leukaemia Key Companies
Appendix
Executive Summary
Chronic myelomonocytic leukaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tefinostat: Chroma Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Enasidenib: Servier
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic myelomonocytic leukaemia Key Companies
Chronic myelomonocytic leukaemia Key Products
Chronic myelomonocytic leukaemia- Unmet Needs
Chronic myelomonocytic leukaemia- Market Drivers and Barriers
Chronic myelomonocytic leukaemia- Future Perspectives and Conclusion
Chronic myelomonocytic leukaemia Analyst Views
Chronic myelomonocytic leukaemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic myelomonocytic leukaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic myelomonocytic leukaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic myelomonocytic leukaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic myelomonocytic leukaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products